Cetrorelix Acetate Patent Expiration

Cetrorelix Acetate is Used for preventing premature LH surges in women undergoing controlled ovarian stimulation. It was first introduced by Emd Serono Inc in its drug Cetrotide on Aug 11, 2000. 5 different companies have introduced drugs containing Cetrorelix Acetate.


Cetrorelix Acetate Patents

Given below is the list of patents protecting Cetrorelix Acetate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Cetrotide US6319192 Method for the treatment of fertility disorders Apr 23, 2019

(Expired)

Emd Serono Inc
Cetrotide US6863891 Oligopeptide lyophilisate, their preparation and use Feb 22, 2014

(Expired)

Emd Serono Inc
Cetrotide US7605121 Oligopeptide lyophilisate, their preparation and use Feb 22, 2014

(Expired)

Emd Serono Inc



Cetrorelix Acetate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Cetrorelix Acetate Generic API Manufacturers

Several generic applications have been filed for Cetrorelix Acetate. The first generic version for Cetrorelix Acetate was by Teva Pharmaceuticals Inc and was approved on Aug 12, 2022. And the latest generic version is by Gland Pharma Ltd and was approved on Apr 25, 2024.

Given below is the list of companies who have filed for Cetrorelix Acetate generic, along with the locations of their manufacturing plants worldwide.


1. GLAND

Gland Pharma Ltd has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Gland.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/VIAL

powder Prescription SUBCUTANEOUS AP Apr 25, 2024


Manufacturing Plant Locations
New

Gland's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Gland as present at those locations.

Country City Firm Name
India
Visakhapatnam Gland Pharma Limited
Malur Gland Chemicals Pvt Ltd.
Hyderabad Gland Pharma Limited, Units I+II Pashamylaram Site
Aurangabad Gland Chemical Private Limited
Sriperumbudur Gland Chemical Private Limited
Hyderabad Gland Pharma Limited
Parawada, Visakhapatnam Gland Pharma Limited





2. LIVZON GRP

Livzon Group Pharmaceutical Factory has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Livzon Grp.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/VIAL

powder Prescription SUBCUTANEOUS AP Apr 24, 2024





3. QILU

Qilu Pharmaceutical Co Ltd has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Qilu.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/VIAL

powder Prescription SUBCUTANEOUS AP Apr 16, 2024


Manufacturing Plant Locations
New

Qilu's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Qilu as present at those locations.

Country City Firm Name
China
Jinan Qilu Pharmaceutical Co., Ltd. (High Tech Zone Site)
Jinan Qilu Pharmaceutical Co., Ltd.
Haikou Qilu Pharmaceutical (Hainan) Co. Ltd.
Jinan Qilu Antibiotics Pharmaceutical Co. , Ltd.
Hulunbeier Qilu Pharmaceutical Hulun Buir Branch
Dezhou Qilu SYNVA Pharmaceutical Co. Ltd
Hohhot Qilu Pharmaceutical (Inner Mongolia) Co., Ltd.





4. TEVA PHARMS INC

Teva Pharmaceuticals Inc has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Teva Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.25MG BASE/VIAL

powder Prescription SUBCUTANEOUS AP Aug 12, 2022